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Abstract
Introduction: The present study utilized a rodent model of diabetes to examine the rewarding
effects of nicotine as well as negative affective states and physical signs of withdrawal from this
drug. Methods: Separate groups of rats received systemic administration of vehicle or
streptozotocin (STZ), which destroys the insulin-producing beta cells in the pancreas and
elevates plasma glucose levels. Place conditioning procedures were utilized to compare the
rewarding effects of various doses of nicotine (conditioned place preference; CPP) and the
aversive effects of nicotine withdrawal (conditioned place aversion; CPA) in vehicle- and STZtreated rats. CPA and physical signs of withdrawal were compared following administration of
the nicotine receptor antagonist mecamylamine to precipitate withdrawal in rats that had received
nicotine exposure for 7-14 days. Control rats received a sham surgical procedure. A subsequent
study compared anxiety-like behavior produced by nicotine withdrawal in vehicle- and STZtreated rats. Anxiety-like behavior was assessed using the elevated plus maze (EPM) and lightdark transfer (LDT) tests. Results: STZ-treated rats displayed CPP across a wider dose range of
nicotine and a larger magnitude of CPA produced by withdrawal as compared to controls. STZtreated rats also displayed significantly higher levels of physical signs of withdrawal as
compared to controls. STZ-treated rats also displayed higher levels of anxiety-like behavior
produced by nicotine withdrawal on both the EPM and LDT tests. Conclusion: Our findings
suggest that both nicotine reward and withdrawal from this drug are enhanced in a rodent model
of diabetes. Our findings imply that the strong behavioral effects of nicotine promote tobacco use
in persons with metabolic disorders, such as diabetes.
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Chapter 1: Introduction
1.1 Tobacco use is a public health and economic concern
In the United States, tobacco use is the leading contributing factor to preventable disease
and death (Centers for Disease Control & Prevention [CDC], 2016). Approximately 440,000
people in the United States and 4 million people worldwide die each year from tobacco-related
illnesses (Giovino, 2002). For example, long-term tobacco use leads to negative health
consequences such as lung cancer, cardiovascular disease, and emphysema (D’Alessandro et al.,
2012; Hecht, 2012; Milara & Cortijo, 2012). Tobacco use is also an economic burden, as each
year the cost associated with tobacco use exceeds 300 billion dollars (CDC, 2016). Given the
magnitude of problems associated with tobacco use, more research is needed to understand the
various factors that promote smoking behavior in certain sub-populations that are more
vulnerable to smoking, including persons with metabolic disorders, such as diabetes.
1.2 Tobacco use in persons with diabetes
Epidemiological studies have revealed that individuals with metabolic disorders, such as
diabetes are more likely to engage in tobacco use and have a harder time quitting smoking (Gill
et al., 2005). Moreover, the recent decline in smoking rates has been shown to be lower in
persons with diabetes (Fan et al., 2013). Clinical reports further suggest that persons with
diabetes report that they are less likely to quit smoking as compared to non-diabetic persons
(Solberg et al., 2004). Persons with diabetes also display reduced awareness of smoking
cessation approaches, and they generally consider smoking interventions to be unsafe (Gill et al.,
2005).
Persons with diabetes that smoke display higher rates of negative affect, stress, and
depression-like symptoms as compared to diabetic persons that do not smoke (Tonstad et al.,

1

2009). These studies suggest that persons with diabetes may have a greater pre-disposition to
smoke as a tool to cope with mental health issues. There are an array of other factors that might
also promote tobacco use in persons with diabetes, such as control of appetite, weight gain, and
pain management. Although persons with diabetes appear to be more vulnerable to tobacco use,
the factors that promote tobacco use in this sub-population are presently unclear. Thus, this
dissertation will examine the behavioral effects of nicotine in a rodent model of diabetes.
1.3 Nicotine modulates tobacco use
Of the 4,800+ chemicals that are found in tobacco products, nicotine has been shown to
be the primary habit forming compound (Stolerman, & Jarvis, 1995). In humans, nicotine
administration induces feelings of euphoria, alertness, and relaxation (Heishman et al., 2010;
Hukkanen et al., 2005; Le Foll & Goldberg, 2006; 2009; NIDA, 2009). In animals, nicotine is
readily self-administered by humans, dogs, rodents, and primates (Caille, 2012; Corrigall, 1999;
Harvey et al., 2004; Katner et al., 2004; Le Foll et al., 2007; Le Foll & Goldberg, 2006; 2009;
Risner et al., 1983). In the early stages of nicotine addiction, tobacco use is largely motivated by
experiencing the positive rewarding effects of nicotine. However, following chronic tobacco use,
smoking abstinence elicits a withdrawal syndrome that consists of both physical and affective
states, such as intense craving, anxiety, and depression. Indeed, the emergence of these physical
and affective states produced by nicotine withdrawal has been closely associated with the
development of nicotine dependence and relapse behavior (Hughes, 2007; Piper et al., 2011;
Ríos-Bedoya et al., 2008; West et al., 2006). Thus, both the positive rewarding effects of nicotine
and avoiding the negative consequences of withdrawal both play a role in continued tobacco use
and relapse behavior. Understanding both nicotine reward and the aversive effects of withdrawal
from this drug are important to consider when assessing vulnerability to tobacco use. Therefore,
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the present dissertation studies include an examination of both nicotine reward and withdrawal
from this drug in a rodent model of diabetes.
1.4 Nicotine dependence in rodents
Nicotine dependence can be induced in rodents via chronic administration of nicotine via
a subcutaneously implanted osmotic pump (Malin & Goyarzu, 2009). The pump is filled with
nicotine and is then surgically implanted subcutaneously under the rodents back. The nicotine is
delivered via osmosis at a constant rate in a dose range of 3-9 mg/kg/per day (Hamilton et al.,
2010; 2009; Kolokotroni et al., 2012; Malin et al., 2001; 2009; O’Dell et al., 2006; 2007).
Previous work in our laboratory has revealed that nicotine must be delivered for at least 7 days in
order to induce nicotine dependence, as evidenced by the emergence of physical signs of
withdrawal following pump removal (spontaneous withdrawal) or administration of a nACHr
antagonist, such as mecamylamine (precipitated withdrawal). Both spontaneous and precipitated
nicotine withdrawal elicits physical signs and negative affective states. The physical signs of
withdrawal include writhes, gasps, shakes, tremors, teeth chattering, chewing, and ptosis
(Hamilton et al., 2009; 2010; Malin et al., 1992; Malin & Goyarzu, 2009; Skjei & Markou,
2003). The negative affective states of withdrawal can be assessed using place-conditioning
procedures, where animals avoid a compartment paired previously with nicotine withdrawal
(Bruijnzeel, 2012; O’Dell & Khroyan, 2009). Negative affective states produced by nicotine
withdrawal have been assessed in behavioral procedures that measure anxiety-like behavior, as
described below.
Previous studies have revealed that the physical signs and negative affective states
produced by nicotine withdrawal are distinctly mediated. Specifically, previous studies have
shown that the physical signs of nicotine withdrawal are mediated via central and peripheral
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nicotinic acetylcholine receptors (nAChRs), whereas affective states produced by withdrawal are
mediated via central nervous systems nAChRs (De Biasi & Dani, 2011; Watkins et al., 2000).
Moreover, work in our laboratory has shown that adolescent rats display fewer physical signs
and affective states as compared to adults experiencing nicotine withdrawal (O’Dell et al., 2006;
2007). Also, pre-clinical reports have shown that female rats display greater negative affective
states, but similar physical signs of nicotine withdrawal as compared to males (Carcoba et al.,
2016). These group differences suggest that the physical and affective states produced by
nicotine withdrawal are distinctly mediated. Therefore, this dissertation will assess physical signs
and affective states produced by nicotine withdrawal in a rodent model of diabetes.
1.5 Place conditioning in rodents
Place conditioning is a behavioral approach that utilizes Pavlovian principles to assess the
motivational effects of nicotine (Tzschentke, 1998). This paradigm employs a conditioning
apparatus that consists of 2 distinct compartments that differ in sensory modalities for visual
stimuli (stripped versus solid walls), tactile cues (smooth versus serrated floors), and odors (pine
versus cedar bedding). The chamber is separated by a solid removable door that can be replaced
with another door that has an opening in it that allows the rat to pass freely between the 2 sides
of the chamber. This dissertation employs a biased design, whereby rats are pre-tested for their
initial preference for either side of the conditioning chamber. During conditioning, the rats are
given an injection of nicotine and are confined to their initially non-preferred compartment (i.e.,
the side they spent less than 50% of their time in during the pre-test). On intervening days, the
rats are given an injection of saline and are confined to the alternate compartment. During
conditioning, the rats form an association between the environmental cues (conditioned stimuli;
CS) and the affective states produced by nicotine (unconditioned stimuli; US). Following
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conditioning, the rats are given free access to both compartments simultaneously in the absence
of drug. The rewarding effects of nicotine are evident as a positive shift in preference behavior
for the environment paired with nicotine (i.e., conditioned place preference; CPP). However, the
aversive effects of high doses of nicotine can also be observed as a negative shift in preference
behavior (conditioned place aversion; CPA). Thus, an important advantage of the place
conditioning procedure is that it has the ability to assess both the positive rewarding effects of
nicotine as well as negative affective states produced by high doses of this drug. Indeed, previous
studies have revealed that doses of nicotine within a dose range of 0.2-0.6 mg/kg produce CPP,
whereas nicotine doses within a range of 0.8-1.2 mg/kg produce CPA in adult male rats (Le Foll
& Goldberg, 2005; Torres et al., 2009).
Place conditioning procedures can also be used to measure aversive effects induced by
nicotine withdrawal. In these studies, animals first receive chronic nicotine exposure via osmotic
pumps for 5-7 days. During conditioning, the animal receives a nicotinic receptor antagonist
(such as mecamylamine) to precipitate withdrawal and is confined to one side of the apparatus.
On alternating days they receive saline in the other compartment. In this procedure, the rat
receives mecamylamine in their initially preferred side, such that a negative shift in preference
indicates a CPA. It has been well established, that following conditioning, nicotine-dependent
adult rats reliably display a CPA for the compartment where they experienced nicotine
withdrawal (O'Dell et al., 2007; Suzuki et al., 1996). In CPA studies, the negative affective state
produced by withdrawal serves as the US and the environmental cues serve as the CS. Previous
studies have revealed that nicotine withdrawal produces CPA in a linear manner, with higher
doses of mecamylamine producing a larger magnitude of aversion in adult male rats (O’Dell et
al., 2007).
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1.6 Anxiety-like behavior in rodents
The elevated plus maze (EPM) is a well-established procedure for assessing anxiety-like
behavior in rodents (Bertoglio & Carobrez, 2002; Crawley, 2007; Pello & File, 1986; Rodgers &
Dalvi, 1997; Rodgers et al., 1997). The apparatus consists of a 4-arm maze that is elevated 2 feet
from the floor. Typically, enclosed walls surround 2 of the arms and the other 2 arms are on
unprotected open platforms (Bourin et al., 2007). During EPM testing, time spent in the open,
center, and closed arms are recorded (Walf & Frye, 2007). This behavioral test takes advantage
of a rodent’s natural tendency to explore novel environments and to avoid elevated and open
areas. This test places the animal in an approach/avoidance conflict that induces the release of
stress markers in rodents (Holmes et al., 2003). An animal that experiences anxiety will spend
more time in the closed versus open arms as compared to a control rat that is relatively less
stressed (Overstreet, 2012).
The light-dark transfer (LDT) procedure is another behavioral test that assesses anxietylike behavior in rodents. The LDT apparatus consists of a protected and dark compartment and
an unprotected and well-lit compartment. During LDT testing, time spent in the light versus dark
areas of the apparatus, transitions between compartments, and total entries into each side are
recorded (Bailey & Crawley, 2009). A stressed animal will spend more time in the dark side of
the apparatus as compared to a control rat that is presumably less stressed. The LDT and EPM
procedures are similar in that they both place the animal in an approach/avoidance situation. This
dissertation will employ both EPM and LDT tests in order to provide converging lines of
evidence with regard to our assessments of anxiety-like behavior produced by nicotine
withdrawal. These tests are an important addition to our experimental design, given that the CPA
procedure does not provide explicit information about the nature of the aversive state produced
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with nicotine withdrawal.
Previous research has shown that animals experiencing nicotine withdrawal display an
increase in anxiety-like behavior (Bruijnzeel et al., 2012; O’Dell, 2009). For example, both
precipitated and spontaneous nicotine withdrawal produces an increase in time spent in the
closed arm of the EPM relative to control rats (Chae et al., 2007; Irvine et al., 2001; Jonkman et
al., 2008; Tejeda et al., 2012; Wilmouth & Spear, 2006). Nicotine withdrawal has also been
shown to produce an increase in time spent in the dark side of the LDT apparatus as compared to
control rats (Jonkman et al., 2005; Stoker et al., 2008). These reports suggest that nicotine
withdrawal produces an increase in anxiety-like behavior that can be assessed using both EPM
and LDT procedures.
1.7 Rodent models of diabetes
Diabetes is a complex disease that can be studied using an array of animal models. The
underlying characteristic of Type 1 diabetes is a lack of insulin production from the pancreas.
Various approaches have been used to study Type 1 diabetes, including genetic, viral, or
chemical induction of a diabetic state. One of the most common approaches in diabetes research
involves chemical induction of hypoinsulinemia via administration of streptozotocin (STZ). This
compound has a similar structure to glucose, and as a result, is taken up via glucose (Type 2)
transporters that are highly concentrated on insulin-producing beta cells in the pancreas. Once
inside the cell, STZ causes DNA alkylation and activation of PARP-1, which depletes NAD+
and produces cell death (Sandler & Swenne, 1983). Since STZ is toxic to these cells, it produces
a profound decrease in insulin (hypoinsulinemia) and a concomitant increase in blood glucose
(hyperglycemia). This compound is a widely used and reliable method for studying diabetes in
rodents (Artinano & Castro, 2009; Lee et al., 2010).
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The underlying characteristic of Type 2 diabetes is insulin resistance that also results in
elevated blood glucose levels. Various types of approaches are used to study Type 2 diabetes,
involving selective breeding or consumption of a high-fat diet (HFD) regimen. Chronic
administration of a HFD regimen produces obesity, hyperinsulinemia, and hyperglycemia
(Baladi et al., 2011; Winzell & Ahren, 2004; Woods et al., 2003). The percentage of fat content
and the length of the regimen are important factors that influence the development of insulin
resistance. The standard HFD regimen consists of >30% fat content with a regimen that lasts 420 weeks to establish insulin resistance (Baladi et al., 2011; Buettner et al., 2007).
Although there are several different approaches to induce a diabetic state in rodents, this
dissertation will employ the STZ model for the following reasons. First, the STZ model provides
a rapid induction of hypoinsulinemia that is well characterized in our laboratory. Second, the
present dissertation studies will extend previous work in our laboratory showing that STZ-treated
rats display greater nicotine self-administration as compared to vehicle controls (O’Dell et al.,
2014). This study suggests that the rewarding effects of nicotine are enhanced in rodent models
involving a disruption in insulin signaling. However, it remains unclear whether STZ
administration would produce an enhancement in the aversive effects of high doses of nicotine
and/or negative affective states or physical signs produced by nicotine withdrawal.
1.8 Dissertation aims and hypotheses
This dissertation will utilize place-conditioning procedures to compare both the
rewarding effects of nicotine (CPP) and the aversive effects of nicotine withdrawal (CPA) in
vehicle- and STZ-treated rats. Previous studies have focused primarily on the rewarding effects
of nicotine. Since place-conditioning procedures assess both rewarding properties and aversive
states in the same experimental procedure, this dissertation expands previous work by comparing
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both nicotine reward and withdrawal in a rodent model of diabetes. In addition, the application of
place conditioning procedures allows for concomitant assessment of the physical signs of
withdrawal during conditioning in the CPA study. This dissertation also expands previous work
by comparing anxiety-like behavior produced by nicotine withdrawal in a rodent model of
diabetes.
This dissertation is organized into 2 Specific Aims that compare the rewarding effects of
nicotine (Aim 1) and the negative effects of nicotine withdrawal (Aim 2) in vehicle- and STZtreated rats. Aim 1 examined place-conditioning produced by various doses of nicotine in
vehicle- and STZ-treated rats. Aim 2 utilized CPA procedures to compare the aversive effects of
nicotine withdrawal in vehicle- and STZ-treated rats. CPA and physical signs were examined in
nicotine-dependent rats following administration of the nicotine receptor antagonist
mecamylamine to precipitate withdrawal. Aim 2 also utilized EPM and LDT procedures to
compare anxiety-like behavior produced by nicotine withdrawal in vehicle- and STZ-treated rats.
Our hypotheses for Aims 1 and
2 are shown in the diagram to the right.
The goal of Aim 1 was to characterize
place-conditioning

produced

by

nicotine in a rodent model of diabetes.
Our hypothesis was that STZ-treated
rats will display greater rewarding
effects of nicotine as compared to controls. Our hypothesis was based on previous studies in our
laboratory showing that STZ-treated rats display higher levels of nicotine self-administration as
compared to vehicle controls (O’Dell et al., 2014). The goal of Aim 2 was to characterize the
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aversive effects of nicotine withdrawal in a rodent model of diabetes. Our hypothesis was that
STZ-treated rats would display greater aversive effects of nicotine withdrawal as compared to
vehicle controls. To our knowledge, there are no pre-clinical reports that have compared the
negative affective states produced by nicotine withdrawal in a rodent model of diabetes.
Therefore, our hypothesis is based largely on clinical studies that have revealed that individuals
with diabetes display higher levels of anxiety and depression, and they also have a harder time
quitting smoking (Eliasson et al., 1997; Fan et al., 2013; Haire-Joshu et al., 1994; Spangler et al.,
2001).
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Chapter 2: Methods
2.1 Subjects
Male Wistar rats were obtained from an out-bred stock of animals (Envigo, Inc.,
Indianapolis, IN). Each experimental group consisted of rats from distinct litters that were
housed in a humidity- and temperature-controlled (22°C) vivarium on a 12-hr light/dark cycle
(lights off at 8:30 am and on at 8:30 pm). The rats were group-housed with 2-3 same sex
littermates. All of our procedures were approved by our Institutional Animal Care and Use
Committee.
2.2 Overall design
This dissertation consisted of 3 studies that were conducted in separate cohorts of rats.
The objectives of Aim 1 were examined in Study 1, and the objectives of Aim 2 were examined
in Studies 2 and 3. Specifically, Study 1 compared place-conditioning produced by nicotine
using CPP procedures in vehicle- and STZ-treated rats. Study 2 compared the aversive effects of
nicotine withdrawal using CPA procedures in vehicle- and STZ-treated rats. The physical signs
of withdrawal were also assessed on the last 2 days of conditioning following saline and
mecamylamine administration. An additional group of STZ-treated rats that did not receive
nicotine exposure were conditioned in the CPA procedure in order to examine the effects of
mecamylamine alone in STZ-treated rats. Study 3 compared anxiety-like behavior produced by
nicotine withdrawal in vehicle- and STZ-treated rats.
In each study, the rats first received vehicle (citrate buffer) or STZ (45 mg/kg; expressed
as salt) administration. Fresh solutions of STZ were prepared for each cohort, and the drug was
administered within 15 min of preparation. Glucose levels were monitored every other day after
STZ administration. A small sample of blood was expressed on a test strip that was inserted into
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a glucometer that is appropriate for rodent blood plasma (AlphaTRAK, Abbott Laboratories,
Inc.). STZ increased glucose levels within approximately 3-5 days after STZ administration
within a range of approximately 250-550 mg/dL. Animals that displayed average glucose levels
higher than 550 mg/dL were eliminated from our analysis. Vehicle-treated rats displayed glucose
levels in a range of approximately 120-160 mg/dL. The rats were conditioned and tested
approximately 2 weeks after vehicle or STZ administration.
2.3 Place conditioning procedures
Our conditioning chambers consisted of 2 distinct compartments of equal proportions (76
× 24 × 30 cm) that were separated by a removable solid partition. There were 1-way mirrors on
the front walls to allow for behavioral observations. One compartment had black walls with pine
bedding beneath a smooth Plexiglas® floor with small holes. The other compartment had black
and white stripped walls with a mixture of pine bedding and blue paper chips beneath a textured
Plexiglas® floor with small holes. Both compartments were equally illuminated, and there was
continuous white noise (0-20 kHz) in the room to minimize any disturbances from outside the
test area.
This dissertation employed a biased procedure that consisted of 3 phases: an initial pretest, 8 conditioning days, and a final post-test. The conditioning phase consisted of 4 drug
pairings and 4 saline pairings. In order to test for preference behavior, the solid partition that
separated the compartments was removed and replaced with a partition that had an opening in
the center (8 × 8 cm high). The rats were allowed to shuttle freely between the compartments for
15 min. Rats that displayed an initial preference of greater than 65% were eliminated from the
study. Five days after the initial preference test, the 8-day conditioning phase of the study was
initiated using 30-min sessions. The day after the last conditioning session, the rats were re-
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tested for shifts in preference behavior for 15 min. In each study, the order of drug treatment was
counterbalanced within treatment groups such that some rats received drug on the first day of
conditioning and the other half of rats received drug on the second day of conditioning.
Study 1 compared CPP produced by various doses of nicotine in vehicle- and STZtreated rats. During conditioning, separate groups of rats received either saline (n=7 vehicle; n=5
STZ) or various doses of nicotine (0.1 [n=6 vehicle; n=6 STZ], 0.2 [n=11 vehicle; n=9 STZ], 0.4
[n=9 vehicle; n=12 STZ], or 0.8 [n=8 vehicle; n=6 STZ] mg/kg). Immediately following the
injection, the rats were placed into their initially non-preferred side for 30 min. (-)Nicotinehydrogen tartrate (Sigma Aldrich, Inc.) was dissolved in 0.9% sterile saline and administered
subcutaneously in a volume of 1 ml/kg (expressed as base). The range of nicotine doses was
selected based on previous research in our laboratory employing CPP procedures with adult rats
(Torres et al., 2008).
Study 2 compared CPA produced by nicotine withdrawal in vehicle- and STZ-treated
rats. Twelve days after vehicle or STZ administration, the rats were anesthetized (1-3%
isoflurane) and surgically prepared with an osmotic pump (Alzet model 2ML2, Durect
Corporation, Inc.) that delivered nicotine (3.2 mg/kg/expressed as base) for 14 days. An
additional group of STZ-treated rats were given a sham surgery and did not receive nicotine
exposure in order to examine the effects of mecamylamine alone in STZ-treated rats. The
concentration of nicotine in the pump was adjusted based on the animals’ weight on the day of
surgery. Two days after surgery, the rats were tested for their initial preference behavior. Five
days later, separate groups of nicotine-exposed rats received subcutaneous administration of
either saline (n=14 vehicle; n=8 STZ) or various doses of mecamylamine (0.75 [n=13 vehicle;
n=5 STZ], 1.5 [n=14 vehicle; n=8 STZ], or 3.0 [n=12 vehicle; n=7 STZ] mg/kg/expressed as
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salt) to precipitate withdrawal in their initially preferred side. The STZ-treated rats that did not
receive nicotine pumps were conditioned with the highest doses of mecamylamine (1.5 [n=7
STZ] or 3.0 [n=7 STZ] mg/kg). (-)Mecamylamine hydrochloride (Sigma Aldrich, Inc.) was
dissolved in sterile 0.9% saline solution and administered in a volume of 1 ml/kg. The range of
mecamylamine doses was chosen based on previous studies showing that these doses precipitate
physical signs and negative affective states during nicotine withdrawal in healthy adult rats
(O'Dell et al., 2006; 2007).
The physical signs of withdrawal were compared on the last 2 days of conditioning
following saline or mecamylamine administration. Somatic signs were recorded by an observer
that was blind to the animals’ treatment condition. The frequency of occurrence of the following
signs was recorded for 10 min: eye blinks, body shakes, gasps, yawns, headshakes, ptosis, and
teeth chattering. Multiple successive counts of any sign required a distinct pause between
episodes. If present continuously, ptosis was counted only once.
2.4 Anxiety-like behavior assessments
Study 3 compared anxiety-like behavior produced by nicotine withdrawal using EPM and
LDT procedures. The EPM apparatus consists of 4 arms (10 × 50 cm) that are elevated to a
height of 50 cm above the ground. The closed arm of the EPM has 20 cm high walls around it
and the open arms do not have walls to enclose the open arm platform. The LDT apparatus
consists of a Plexiglas® box that is separated into a light side (25 × 25 × 35cm) and a smaller but
connected dark side (25 × 25 × 23 cm) with an opening (10 × 10 cm) in the center that allows the
rat to move freely between both sides.
Fourteen-days after vehicle or STZ administration, the rats were implanted with osmotic
pumps that delivered nicotine for 14 days, as described above. Anxiety-like behavior produced

14

by nicotine withdrawal was compared following 7 days of nicotine exposure using EPM
procedures and again following 14 days of nicotine exposure using LDT procedures. During
each test, separate groups of vehicle- or STZ-treated rats received subcutaneous administration
of either saline (n=15 vehicle; n=9 STZ) or the 1.5 mg/kg (n=9 vehicle; n=9 STZ) or 3.0 mg/kg
(n=9 vehicle; n=9 STZ) dose of mecamylamine. For the EPM test, the rats were first acclimated
to the testing room in a rectangular Plexiglas® cage for 10 min, and then they received saline or
mecamylamine administration. Ten min later, they were placed in the center of the EPM
apparatus facing the open arm. Time spent in the closed versus open arms was recorded for 5
min. For the LDT test, the rats were re-acclimated to the testing room in a rectangular Plexiglas®
cage for 10 min, and then received saline or mecamylamine administration. Ten min later, they
were placed into the dark side of the LDT apparatus. Time spent in the light versus dark side of
the apparatus was recorded for 5 min. Both the EPM and LDT test chambers were located in the
middle of their respective testing rooms beneath a red light. Each apparatus was thoroughly
cleaned with 70% ethanol and then water between each test.
2.5 Statistical approach
With regard to dependent variables, pre- and post-test scores were compared to assess
shifts in time spent in initially non-preferred side following nicotine administration (Study 1) or
in the initially preferred side following mecamylamine administration (Study 2). CPP was
operationally defined as a significant increase in time spent on the initially non-preferred side
after conditioning, whereas CPA was defined as a decrease in time spent on the initially
preferred compartment after conditioning. Mean total signs of withdrawal were compared
following saline versus mecamylamine administration in nicotine-exposed and nicotine-naïve
rats. Time spent in the open versus closed arm of the EPM apparatus and light versus dark side
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of the LDT apparatus (Study 3) were compared in vehicle- and STZ-treated rats. Anxiety-like
behavior was operationally defined as a significant increase in time spent in the closed arm of the
EPM or the dark side of the LDT as compared to controls. Blood glucose levels were compared
across groups after the post-test in Study 1 and 2. Average glucose levels were compared across
treatment groups during the EPM and LDT tests in Study 3.
With regard to our statistical approach, the place conditioning data were analyzed using a
mixed-measures ANOVA with day as a within subject factor (pre- versus post-test) and dose of
nicotine or mecamylamine, state (vehicle versus STZ or nicotine exposed versus naïve) as
between subject factors. A trend analyses was used to assess the curvature of the CPP doseresponse curve and the linearity of CPA with increasing doses of mecamylamine. The physical
signs of withdrawal were analyzed using day as a within-subjects factor (saline versus
mecamylamine) and dose (mecamylamine) and state (vehicle or STZ) as between subject factors.
For the additional group of STZ-treated rats that did not receive nicotine exposure, these data
were analyzed using day as within-subjects factor (saline versus mecamylamine) and dose
(mecamylamine) and state (nicotine exposed versus naïve) as between subject factors. For
anxiety-like behavior, the data were analyzed using 2-way ANOVA with dose of mecamylamine
and state (vehicle or STZ) as between subject factors. Subsequent planned comparisons were
assessed between groups using a Bonferonni correction factor that reduced our p value to an
appropriate level based upon the number of comparisons that were made in each figure. Glucose
levels were compared using 2-way ANOVA with dose (nicotine or mecamylamine) and state
(vehicle or STZ) as between subject factors.
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Chapter 3: Results
3.1 CPP
Figure 1 reflects CPP produced by nicotine in vehicle- and STZ-treated rats from Study
1. Although our CPP curves did appear to be an inverted U-shape, our quadratic trend analysis
did not reach statistical significance (p=0.94). A subsequent ANOVA analysis revealed a
significant interaction between day and state [F(1,69) = 4.7, p≤0.05], with STZ-treated rats
displaying a larger upward shift in time spent in their initially non-preferred side as compared to
vehicle-treated controls. Indeed, a significant increase in time spent in the initially non-preferred
compartment was observed in vehicle-treated rats that received the 0.2 mg/kg dose and STZtreated rats that received the 0.2 and 0.4 mg/kg dose of nicotine (*p≤0.01).
3.2 CPA
Figure 2 reflects CPA produced by nicotine withdrawal in vehicle- and STZ-treated rats
from Study 2. Our linear trend analysis revealed that nicotine withdrawal produced CPA that
increased across mecamylamine doses in a linear manner in both treatment groups (p≤0.05). Our
subsequent ANOVA analysis revealed a significant interaction between day and dose [F(3,73) =
3.1, p≤0.05], indicating that higher doses of mecamylamine produced a larger magnitude CPA.
Indeed, a significant decrease in time spent in the initially preferred compartment was observed
in vehicle-treated rats that received the 3.0 mg/kg dose and STZ-treated rats that received the 1.5
and 3.0 mg/kg dose of mecamylamine (*p≤0.01). A separate control group of STZ-treated rats
were included that did not receive nicotine exposure (data not shown). In the absence of nicotine,
mecamylamine did not produce a decrease in time spent in the initially preferred compartment
(1.5 mg/kg dose of mecamylamine pre-test value 𝑥=506.6±16.7 and post-test value
𝑥=476.0±45.0; 3.0 mg/kg dose of mecamylamine pre-test value 𝑥=529.0±16.0 and post-test
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value 𝑥=526.8±55.1). These data show that the effects of mecamylamine in STZ-treated rats are
uniquely exacerbated in nicotine-dependent rats.
3.3 Physical signs
Figure 3 reflects the total physical signs of withdrawal (top panel) and individual counts
of body shakes (bottom panel) in vehicle- and STZ-treated rats from Study 2. Our analyses
revealed a significant interaction of day, state, and dose [F(3,68) = 3.7, p≤0.05], indicating that
the physical signs of withdrawal were dose-dependently increased in STZ- versus vehicle-treated
rats. Specifically, a significant increase in physical signs was observed in vehicle-treated rats
following administration of the 1.5 and 3.0 mg/kg dose of mecamylamine and STZ-treated rats
that received the 1.5 and 3.0 mg/kg dose of mecamylamine (*p≤0.01). Importantly, the
magnitude of this effect was larger in STZ-treated rats that received the 3.0 mg/kg dose as
compared to vehicle-treated controls (†p≤0.01).
Our analyses of body shakes revealed a significant interaction of day, state, and dose
[F(3,68) = 2.9, p≤0.05], indicating that body shakes were dose-dependently higher in STZversus vehicle-treated rats during withdrawal. Specifically, a significant increase in body shakes
was observed in STZ-treated rats that received the 3.0 dose of mecamylamine (*p≤0.01), and the
magnitude of this effect was larger in STZ- versus vehicle-treated controls (†p≤0.01).
A separate control group of STZ-treated rats were included that did not receive nicotine
exposure (data not shown). Our analysis revealed that in the absence of nicotine, there was no
difference in the total physical signs of withdrawal following saline (1.5 mg/kg treatment group
𝑥=4.3±0.6; 3.0 mg/kg treatment group 𝑥=5.1±1.7) or mecamylamine (1.5 mg/kg dose of
mecamylamine, 𝑥=4.9±1.1; 3.0 mg/kg dose of mecamylamine, 𝑥=3.6±0.9) administration during
the last 2 days of conditioning. These data show that the effects of mecamylamine in STZ-treated
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rats are uniquely exacerbated in rats that received nicotine exposure.
3.4 EPM
Figure 4 reflects the percent time spent in the closed arms of the EPM. Our trend analysis
revealed that nicotine withdrawal increased time spent in the closed arms in a linear manner with
increasing doses of mecamylamine in STZ-treated rats (linear trend; p≤0.05). Subsequent
analyses revealed a significant interaction of state and dose [F(2,54) = 7.5, p≤0.05], indicating
that STZ- treated rats displayed a dose-dependent increase in time spent in the closed arms of the
EPM. Indeed, a significant increase in time spent in the closed arms was observed in vehicletreated rats that received the 3.0 mg/kg dose and STZ-treated rats that received the 1.5 and 3.0
mg/kg dose of mecamylamine as compared to their respective saline controls (*p≤0.02).
Importantly, the magnitude of this effect was larger in STZ-treated rats that received the 1.5
mg/kg dose of mecamylamine as compared to vehicle-treated controls (†p≤0.02).
3.5 LDT
Figure 5 reflects the percent time spent in the dark area of the LDT. Our trend analysis
revealed that the mecamylamine elicited a linear increase in time spent in the dark area with
increasing doses of mecamylamine (p≤0.05). Subsequent analyses revealed a main effect of dose
[F(2,54) = 10.6, p≤0.05], indicating that mecamylamine produced an increase in time spent in
the closed area of the LDT. Although we did not observe an overall interaction, subsequent
planned comparisons revealed a significant increase in time spent in the closed area of the LDT
in vehicle-treated rats that received the 3.0 mg/kg dose and STZ-treated rats that received the 1.5
and 3.0 mg/kg dose of mecamylamine (*p≤0.02). The magnitude of this effect was larger in
STZ-treated rats that received the 1.5 mg/kg dose as compared to their respective vehicle-treated
controls (†p≤0.02).
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3.6 Glucose levels
Table 1 reflects glucose values during the post-test days in Study 1 and 2 and the average
levels following the EPM and LDT tests in Study 3. Overall, STZ produced a significant increase
in glucose levels that was similar across treatment conditions in each study. For Study 1 and 2,
our analyses revealed a main effect of state, with STZ-treated rats displaying higher glucose
levels as compared to vehicle-treated controls regardless of their nicotine dose in Study 1
[F(1,69) = 761.5, p≤0.01] or mecamylamine treatment in Study 2 [F(1,73) = 931.2, p≤0.01]. For
Study 3, our analyses also revealed a main effect of state, with STZ-treated rats displaying higher
glucose levels as compared to vehicle-treated rats during the EPM and LDT tests [F(1,54) =
799.4, p≤0.01].
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Chapter 4: Discussion
4.1 Summary
The major findings of this report is that STZ-treated rats experience greater rewarding
effects of nicotine and aversive effects of withdrawal as compared to vehicle-treated controls.
CPP was observed across a wider range of doses of nicotine in STZ- versus vehicle-treated rats.
CPA produced by nicotine withdrawal was observed at a lower dose in STZ- versus vehicletreated rats. Also, the physical signs of withdrawal were greater in STZ- versus vehicle-treated
rats. Lastly, the explicit nature of the aversive effects of nicotine withdrawal are likely related to
an increase in anxiety-like behavior in STZ-treated rats. Together, our results suggest that
diabetes enhances both the rewarding effects of nicotine and negative affective states and
physical signs produced by nicotine withdrawal.
4.2 STZ-treated rats experience strong rewarding effects of nicotine
Our results revealed that nicotine produced CPP in a pattern and dose range consistent
with previous work from our laboratory and others (Fudala et al., 1985; Janhunen et al., 2005; Le
Foll & Goldberg, 2005; Torres et al., 2009). Importantly, CPP produced by nicotine was
observed across a wider range of doses in STZ- versus vehicle-treated rats. This finding suggests
that the rewarding effects of nicotine are enhanced in a rodent model of diabetes. Consistent with
the latter suggestion, previous work in our laboratory demonstrated that STZ-treated rats display
higher levels of nicotine intake in an extended self-administration procedure as compared to
vehicle-treated controls (O’Dell et al., 2014). Also, previous studies revealed that rats that were
fed a HFD regimen and were insulin-resistant displayed CPP at a dose of nicotine that did not
produce this effect in rats that were not insulin resistant (Richardson et al., 2014). Both our IVSA
and CPP data provide converging lines of evidence that the rewarding effects of nicotine are
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enhanced in an animal model of diabetes. It is important to note that one report revealed that
mice placed on a HFD regimen did not display nicotine CPP (Blendy et al., 2005). However, one
possibility that might explain the discrepancy between the Richardson and Blendy et al. studies
is that the mice in the Blendy study were not insulin resistant. The discrepancy in the CPP data
may also be related to differences in nicotine metabolism between rats and mice and/or different
doses of nicotine and routes of administration that were used. Together, the results from this
dissertation and previous reports suggest that diabetes enhances the rewarding effects of nicotine
via a disruption in insulin signaling.
4.3 STZ-treated rats display strong aversive effects of withdrawal
Our results revealed that STZ-treated rats display greater aversive effects of nicotine
withdrawal as compared to controls using CPA procedures. Furthermore, increasing doses of
mecamylamine elicited a larger magnitude of CPA, which is consistent with previous results
from our laboratory and others (O’Dell et al., 2007; Shram et al., 2008). Importantly, CPA was
observed across a wider range of doses and at a lower dose of mecamylamine in STZ- versus
vehicle-treated rats. These data suggest that STZ-treated rats are more sensitive to the aversive
effects of nicotine withdrawal. To our knowledge, the aversive effects of nicotine withdrawal
have not been investigated in an animal model of diabetes. Thus, our findings provide a novel
contribution to the literature regarding nicotine withdrawal in diabetic rats.
4.4 STZ-treated rats display intense physical signs of withdrawal
Another finding of this dissertation is that the physical signs of withdrawal were greater
in STZ- versus vehicle-treated rats. As previously mentioned, nicotine withdrawal produces both
physical signs and negative affective states that contribute to continued tobacco use and relapse
behavior. Previous review papers have suggested that negative affective states produced by
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withdrawal play a larger role in continued use and relapse to smoking as compared to the
physical symptoms produced by nicotine withdrawal (Koob et al., 1993; Markou et al., 1998).
However, a comparison of the magnitude of our group differences between affective tests of
withdrawal versus physical signs, revealed that the largest effects observed in STZ-treated rats
was in our assessment of the physical signs of withdrawal. These data suggest that persons with
diabetes may experience intense physical symptoms during nicotine withdrawal that may
promote tobacco use in this population. Indeed, there are significant negative health
complications associated with diabetes, such as neuropathic pain (Holt et al., 2010) that may
exacerbate the use of tobacco to cope with pain and other peripheral neuropathies. Thus, the
intense physical effects of nicotine withdrawal might explain why diabetic persons have a harder
time quitting smoking in comparison to persons that use tobacco but are not diabetic.
4.5 STZ-treated rats experience greater anxiety-like behavior during nicotine withdrawal
Our EPM and LDT results revealed that nicotine withdrawal produced an increase in
anxiety-like behavior that was larger in STZ- versus vehicle-treated rats. When the EPM test was
conducted after 7 days of nicotine exposure, our results revealed that withdrawal produced an
increase in anxiety-like behavior that was larger in STZ- versus vehicle-treated rats. These data
suggest that STZ-treated rats display anxiety-like behavior at an earlier time point of nicotine
dependence as compared to vehicle-treated rats. Notably, our largest group differences were at
the intermediate dose of mecamylamine. One possible explanation for this outcome is that STZtreated rats that received high doses of mecamylamine may have experienced physical stress or
motor impairments that may have influenced our behavioral assessments. In summary, the EPM
and LDT provide a deeper understanding of our CPA results because they suggest that the
increase in the negative affective states observed in STZ-treated rats is related to an enhancement
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of anxiety-like states. Thus, our results suggest that diabetes enhances the negative affective
states produced by nicotine withdrawal.
4.6 Potential mechanisms and future directions
There are several mechanisms that might modulate the strong behavioral effects of
nicotine withdrawal in STZ-treated rats. One likely candidate is dopamine transmission in the
mesolimbic pathway, which originates in the ventral tegmental area and terminates in the nucleus
accumbens (NAcc; Deveto & Flore, 2006; Koob & Kreek, 2007; Wanat et al., 2009). Previous
work has shown nicotine withdrawal produces a decrease in dopamine release in the NAcc in
healthy adult rats (Natividad et al., 2010; Zhang et al., 2012). A recent study in our laboratory
demonstrated that STZ-treated rats display lower basal dopamine levels in the NAcc (O’Dell et
al., 2014). Thus, the possibility exists that the decreases in NAcc dopamine levels that modulate
nicotine withdrawal are exacerbated in STZ-treated rats that already display suppressed basal
dopamine transmission. Future studies are needed to examine whether reduced dopamine levels
promote the aversive effects of withdrawal in rats that display a disruption in insulin signaling.
Indeed, we recently hypothesized that enhanced tobacco use in persons with diabetes is likely
mediated via a suppression of dopamine signaling in the mesolimbic pathway (O’Dell &
Nazarian, 2016). Or hypothesis was based largely on recent theories suggesting that deficits in
the brain dopamine system weaken inhibitory control of excessive pleasure seeking that result in
an increased sensitivity to drugs of abuse (George et al., 2011; Melis, Spiga, & Diana, 2005).
Future studies are needed to examine whether compulsive tobacco use in persons with diabetes is
related to overcompensation for a reward deficiency syndrome that is rooted in suppressed
dopamine neurotransmission. Ongoing work in our laboratory is examining whether insulin
replacement normalizes the strong rewarding effects of nicotine in rodent models of diabetes.
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4.7 Clinical implications
There are several clinical implications from this dissertation. First, our results suggest
that persons with diabetes experience intense rewarding effects of nicotine and heightened
sensitivity to nicotine withdrawal during smoking abstinence. Thus, the strong rewarding effects
of nicotine likely promote the initiation and continued use of tobacco in persons with diabetes.
Also, clinical reports have shown individuals with diabetes display low tobacco cessation rates
and a diminished readiness to quit smoking (Fan et al., 2013; Solberg et al., 2004). They also
display high levels of negative affect, depression, and stress compared to non-diabetic smokers
(Haire-Joshu et al., 1994; Spangler et al., 2001). Thus, intense aversive states of nicotine
withdrawal might promote smoking behavior during the maintenance and abstinence phases of
tobacco dependence in persons with diabetes. Lastly, diabetes may produce dopamine deficits
that are self-medicated with substances that increase dopamine, such as nicotine in tobacco
products. As a result, treatment strategies that normalize dopamine transmission may be effective
for smoking cessation in persons with diabetes. Future studies are needed to elucidate the
underlying mechanisms by which diabetes promotes nicotine reward and withdrawal in order to
develop more effective smoking cessation medications for this vulnerable population.
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Figure 1 depicts vehicle- and STZ-treated rats that were conditioned with various doses of
nicotine in Study 1. The panel reflects time spent (±SEM) in the initially non-preferred
compartment before (pre-test) and after conditioning (post-test). The asterisks (*) denote a
significant difference between pre- versus post-test scores (p≤0.01).
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Figure 2 depicts vehicle- and STZ-treated rats that were conditioned various doses of
mecamylamine in Study 2. The panel reflects time spent (±SEM) in the initially preferred
compartment before (pre-test) and after conditioning (post-test). The asterisks (*) denote a
significant difference between pre- versus post-test scores (p≤0.01).
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Figure 3 depicts mean total physical signs of withdrawal (top panel) (±SEM) and body shakes
(bottom panel) following saline and mecamylamine administration on the last 2 days of
conditioning in Study 2. The asterisks (*) denote a significant difference between saline and
mecamylamine and daggers (†) denote a difference between vehicle- and STZ-treated rats
(p≤0.01).
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Figure 4 depicts mean percent time spent in the closed arm of the EPM (±SEM) following saline
and mecamylamine administration in Study 3. The asterisks (*) denote a significant difference
from saline controls and daggers (†) denote a difference between vehicle- and STZ-treated rats
(p≤0.02).
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Figure 5 depicts mean percent time spent in the dark area of the LDT (±SEM) following saline
and mecamylamine administration in Study 3. The asterisks (*) denote a significant difference
from saline controls and daggers (†) denote a difference between vehicle- and STZ-treated rats
(p≤0.02).
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Oral Presentations
1. Enhanced Rewarding Effects of Nicotine in Diabetic Rats. Presented October 10th, 2013
at the National Hispanic Science Network on Drug Abuse, Bethesda, MD.
2. Adolescent and adult nicotine exposure on the acquisition of methamphetamine selfadministration and the reinstatement of extinguished methamphetamine-seeking in male
rats. Presented October 9th, 2013 at the National Hispanic Science Network on Drug
Abuse, Bethesda, MD.
3. Enhanced Rewarding Effects of Nicotine as assessed by place preference procedures.
Presented June 24th, 2013 at the American Diabetes Association Conference, Chicago,
IL.
4. Adoption of the thin-ideal and body image in Latinas. San Diego State University
Student Presented February 28th, 2009 at the San Diego State University Research
Symposium, San Diego, CA. Winner of the 2009 SDSU-IV Dean’s Award
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Invited Oral Presentations
1. Insulin normalizes the rewarding effects of nicotine in diabetic rats. National Hispanic
Science Network on Drug Abuse, El Paso, TX, 2014.
2. Behavioral and neurochemical effects of chronic paroxetine and fluoxetine exposure in
adolescent rats. National Hispanic Science Network on Drug Abuse, San Diego, CA,
2012.
3. The importance of pre-clinical research on addiction biology. California Association for
Alcohol/Drug Educators, Primm Valley, Nevada, 2011.
4. The physiological effects of alcohol and drugs. Imperial Valley College, Imperial,
California, 2010.
5. The enneagram and the different personality types. Presenter at the XIII Bi-National
Conference on Education Mexicali, Baja California, México 2009.

Teaching Experience
Graduate Teaching Associate
The University of Texas at El Paso
Department of Psychology
Supervisor: Jennifer Enolouoden, Ph.D.

August 2015 - December 2015

Taught Psychology-1301: Introduction to Psychology. I helped design and presented lectures for
all class sessions, proctored exams, held office hours, graded papers and tests.
Graduate Teaching Associate
California State University, San Bernardino
Department of Psychology
Supervisor: Yuchin Chien, Ph.D.

January 2012 - March 2012

Taught Psychology-311 (LAB): Introduction to Psychological Research Methods Class.
Designed and presented lectures for all class sessions, proctored exams, held office hours, graded
papers and tests, supervised psychology experiments for undergraduate students.
Graduate Teaching Assistant
California State University, San Bernardino
Department of Psychology
Supervisor: Allison Kaufman, Ph.D.

January 2011- June 2011

Assisted with instruction of class and conducted lectures, specifically for Biological Psychology
and Drugs & Behavior. Taught classes on Psychopharmacology and Drug Prevention and
relapse.
Undergraduate Teaching Assistant
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San Diego State University, Department of Psychology
Supervisor: Krista L. Byrd, M.A.

January 2010 - May 2010

Graded weekly assignments, exam administration, tutoring, and assisted with lecture for Social
Psychology. 4 hours weekly.

Professional Organizations
Psi Chi – The International Honor Society in Psychology
National Hispanic Science Network on Drug Abuse
Society for Neuroscience
PHI KAPPA PHI Honor Society
Research Society on Alcoholism
Golden Key International Honour Society
APA—Student Affiliate
California Association for Alcohol/Drug Educators

2011 - Present
2011 - Present
2010 - Present
2010 - Present
2010 - Present
2009 - Present
2008 - Present
2007 - Present

Other Professional Activities
Fundraising Chair, General Experimental Psychology Club
2010 - 2011
Advisor: Bob Ricco, Ph.D.
- Help promote knowledge about doctoral programs and careers in psychology.
- Help serve as a social and educational forum for undergraduates and graduates.
President, Psychology Club
2008 - 2010
Advisors: Donna Castañeda, Ph.D. & Elizabeth D. Cordero, Ph.D.
- Re-activated club after two-year hiatus.
- Organized various activities and workshops in the field of psychology.
- Coordinated fundraisers for students to attend the WPA 2010. Fundraised over 3,000
dollars, plus 6,000-dollar SDSU research travel grant recipients.
- Peer Advising about graduate school
Protégé of the Faculty-Student Mentoring Program
San Diego State University-Imperial Valley Campus
Advisor: Elizabeth D. Cordero, Ph.D.
- Involved in research and promoted the essentials of research.
- Had research mentor, specifically to help learn how to write a manuscript.
American Sign Language Club
Advisor: Charles Mason, Instructor of American Sign Language
- Helped interpret for deaf children.
- Fundraising for deaf children to go on field trips.
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2008 - 2010

Fall 2008 - Winter 2008
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